Axsome Therapeutics AXSM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $191.2M-2.4% | $196M+14.6% | $170.99M+14.0% | $150.04M+23.5% | $121.46M+2.3% | ||
| $14.73M+19.4% | $12.33M+3.5% | $11.91M-11.4% | $13.45M+37.4% | $9.79M-6.9% | ||
| $176.48M-3.9% | $183.67M+15.5% | $159.08M+16.5% | $136.59M+22.3% | $111.67M+3.2% | ||
| 92.3%-1.4pp | 93.7%+0.7pp | 93%+2.0pp | 91%-0.9pp | 91.9%+0.8pp | ||
| $52.68M+8.0% | $48.79M+21.5% | $40.16M-18.9% | $49.54M+10.6% | $44.79M-18.6% | ||
| $185M+9.3% | $169.3M+12.7% | $150.24M+15.3% | $130.28M+7.9% | $120.79M+6.6% | ||
| $254.56M+14.2% | $222.96M+2.7% | $217.1M+16.2% | $186.76M+4.7% | $178.45M-6.8% | ||
| -$63.36M-135% | -$26.96M+41.5% | -$46.11M-25.6% | -$36.71M+35.6% | -$56.98M+21.5% | ||
| -33.1%-19.4pp | -13.8%+13.2pp | -27%-2.5pp | -24.5%+22.4pp | -46.9%+14.2pp | ||
| -$64.54M-129% | -$28.13M+40.4% | -$47.23M+3.5% | -$48.93M+17.6% | -$59.41M+20.6% | ||
| $0— | —— | $0+100% | -$960K— | $0-100% | ||
| -$64.54M-126% | -$28.56M+39.5% | -$47.23M+1.6% | -$47.97M+19.3% | -$59.41M+20.7% | ||
| -33.8%-19.2pp | -14.6%+13.0pp | -27.6%+4.4pp | -32%+16.9pp | -48.9%+14.2pp | ||
| -$1.26-129% | -$0.55+41.5% | -$0.94+3.1% | -$0.97+20.5% | -$1.22+20.8% | ||
| -$61.67M-144% | -$25.24M+43.1% | -$44.38M-26.8% | -$35.01M+36.7% | -$55.26M+22.0% | ||
| -32.3%-19.4pp | -12.9%+13.1pp | -26%-2.6pp | -23.3%+22.2pp | -45.5%+14.2pp | ||
| -$63.36M-135% | -$26.96M+41.5% | -$46.11M-25.6% | -$36.71M+35.6% | -$56.98M+21.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $708.2M in revenue over the trailing twelve months, up 63.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $188.3M over the trailing twelve months, a -26.6% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 92.6% and operating margin is -24.4%, with a -26.6% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.72.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
